Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2020

View Archived Issues

Pivotal Japanese study evaluates zandelisib for indolent NHL

First-in-human data presented for BAY-1895344

Positive data from phase IIa NASH study of PXL-770

ZLY-16 shows hepatoprotective effects in mouse model of NASH

Vascular endothelial cells are active co-conspirators in metastasis

Discovery of new allosteric inhibitors of deoxyhypusine synthase

Enanta Pharmaceuticals patents new antivirals

E-Scape Bio discloses LRRK2 inhibitors

Merck & Co. identifies new HDAC inhibitors

New ENPP1 inhibitors presented by Stingray Therapeutics

Lead Discovery Center and SOTIO patent new compounds for cancer

Neural stem cells open to alternate fates

Preliminary first-in-human data presented for CLN-081

European Commission approves Crysvita for adolescents and adults with XLH

MEN-1611 plus trastuzumab +/- fulvestrant well tolerated in phase I breast cancer trial

Revelation Biosciences receives ethics committee approval for phase I study of REVTx-99 for COVID-19

Results reported from nextMONARCH and monarchE studies of abemaciclib

GB-004 advances into phase II for ulcerative colitis

Sorrento initiates phase I study of COVI-GUARD in patients with moderate COVID-19

No delay in progression of ovarian cancer seen with cancer vaccine MVA-5T4 in clinical trial

Xencor presents initial phase I data on tidutamab in neuroendocrine tumors

Ovoca's BP-101 for decreased sexual desire in women not approved in Russia

Phase IIb study of SYN-010 in IBS-C to be discontinued

Apellis advances pegcetacoplan into registrational programs for C3G/IC-MPGN and ALS

IND in effect for Fulcrum's phase I study of FTX-6058 for sickle cell disease